The present study was designed to investigate the efficacy of combination gene therapy using adenoviral vectors expressing gene products shown to possess apoptotic activity: E2F -1 ( Ad -E2F -1 ) and a C -terminal deletion mutant of p21 WAF1 / cIP1 ( Ad -p21 -PCNA ), on growth inhibition and apoptosis of human colon cancer cells in vitro and in vivo. Marked E2F -1 and p21 -PCNA overexpression in response to adenovirus infection was evident by Western blot analysis. IC 25 concentrations of each virus were used for each treatment in vitro to detect cooperative effects on cell death. Coexpression of E2F -1 and p21 -PCNA resulted in an additive effect on cell death compared to infection with either virus alone. Cell cycle analysis, poly( ADP -ribose ) polymerase ( PARP ) cleavage and analysis of cell morphology also revealed that coinfection with both Ad -E2F -1 and Ad -p21 -PCNA enhanced cellular apoptosis compared to either virus alone. Interestingly, E2F -1 protein expression was markedly enhanced in the E2F -1 / p21 -PCNA adenovirus combination compared to Ad -E2F -1 infection alone. However, these same effects were not evident in cells coinfected with Ad -E2F -1 and an adenovirus expressing wild -type human p21 WAF1 / CIP1 ( Ad -p21 WT ). The increase in E2F -1 expression with coexpression of E2F -1 and p21 -PCNA was not a result of increased E2F -1 protein stability, but was related to increased transcriptional activity from the CMV promoter. Cell cycle analysis revealed G1 arrest 72 hours following single -gene therapy with either the wild -type or mutant p21, whereas increased accumulation of cells in G2 / M phase was demonstrated in the E2F -1 -overexpressing cells. In the combined therapies, E2F -1 / p21 -PCNA treatment still resulted in G1 arrest, but E2F -1 was able to counteract the G1 arrest when coinfected with p21
inactivate the proliferating cell nuclear antigen (PCNA ) and CDK2, both of which are E2F -1 transcriptional targets. 19 -24 In a reciprocal manner, E2F -1 can reverse the growth inhibitory effects of p21. 25, 26 Interestingly, a recent study demonstrated that E2F -1 directly transactivates p21, and subsequently, E2F -1 transcriptional activity is inhibited. 27 Collectively, the evidence suggests a feedback loop mechanism between E2F -1 and p21 with apparently opposing activities that involve both direct and indirect interactions. 26, 28, 29 The mechanism( s ) of E2F -1 -mediated apoptosis are not completely elucidated. E2F -1 has been shown to directly transactivate proapoptotic signals such as p14 ARF , a tumor suppressor gene, and p73, a homolog of p53 that can transactivate similar target genes as p53. 30 -32 Interestingly, the apoptotic function of E2F -1 has been shown to be independent of its transcriptional function but dependent on its DNA -binding capability. 33 In light of this finding, a mechanism involving E2F -1-mediated repression of antiapoptotic signals is emerging and is supported by the recent finding that E2F -1 -induced apoptosis is associated with down -modulation of nuclear factor kappaB (NFkappaB ) activity. 34 Although numerous studies show that p21 inhibits apoptosis following a variety of apoptotic stimuli, the only data that exist regarding its effect on E2F -1 -mediated apoptosis come from a study using glioma cells, which showed that p21 did not inhibit E2F -1 -mediated cell death. 35 The ability of p21 to bind and inhibit PCNA and CDK2 are required for the promotion of G1 and G2 cell cycle arrest; 36 however, it is unclear if these functions of p21 are necessary for the inhibition of apoptosis.
A recent study by Zhang et al 37 showed that treatment of cancer cells with the chemotherapeutic drug, camptothecin, resulted in caspase-mediated cleavage of p21 and conversion of the cancer cells from growth arrest to apoptosis. The same study further showed the cleaved p21 fragment lacked the C -terminus and could no longer bind PCNA. These results suggest a potential role for p21:PCNA interaction domain in the inhibition of apoptosis. In support of this theory, Prabhu et al 38 demonstrated that adenovirusmediated expression of a C -terminal deleted p21 gene product that is deficient in binding to PCNA ( Ad -WAF1341, herein called Ad -p21
-PCNA ) inhibited cell cycle progression and induced apoptosis in colon adenocarcinoma cells.
In the present study, we sought to exploit the potential interaction of E2F -1 and p21 -PCNA as a combination gene therapy strategy. Our results indicate that adenovirusmediated coexpression of E2F -1 and p21
-PCNA results in enhanced E2F -1 expression, with additive effects on cell growth inhibition and apoptosis in both colon cancer cell lines in vitro. In an animal model, however, this combination treatment enhanced tumor suppression only in the tumor xenografts established with the metastatic colon cancer cell line, SW620.
Materials and methods

Cells and culture conditions
The colon cancer cell lines, HT-29 ( primary, mutant p53 ) and SW620 (metastatic, mutant p53) ( ATCC, Rockville, MD ) were routinely grown as monolayers in McCoy's 5A medium (Gibco, Grand Island, NY ), supplemented with 10% heat -inactivated fetal bovine serum (Gibco )and penicillin (100 U /mL )/ streptomycin (100 g/ mL ). Both cell lines were cultured in a 5% CO 2 incubator at 378C and subcultured every 4 -5 days. The transformed embryonic kidney cell line 293 was grown in minimum essentialmedium [medium with high glucose (4.6 g /L ), supplemented with 10% FBS and 1% antibiotic /antimiotic ].
Preparation of recombinant adenovirus
The adenovirus AdCMVE2F -1 (referred to herein as Ad -E2F -1 ) was a generous gift from Dr TJ Liu. AdCMVLacZ ( referred to herein as Ad -LacZ ) was a generous gift from Dr Brent French. Dr Walik S. El -Deiry generously provided the AdCMVWAF1 and AdCMVWAF1 -341 viral vectors herein referred to as Ad -p21
WT and Ad -p21 -PCNA , respectively. For preparation of large virus stocks, 293 cells were infected at multiplicity of infection (MOI) 1 -5 and harvested after the cytopathic effect became visible (24 -48 hours ). Cells were harvested and lysed in 1Â PBS + 2 containing 1% sucrose and virus aliquots were stored at À 708C. Titers were determined by plaque assay on 293 cells, as described previously. 4, 5 -Galactosidase assay
The cell lines infected with Ad -LacZ were assayed forgalactosidase expression by the X -gal staining method as described previously. 39 Briefly, 48 hours after infection, the tumor cells were washed with phosphate -buffered saline ( PBS ) and fixed in 2% ( vol /vol ) formaldehyde and 0.2% ( vol /vol ) glutaraldehyde in PBS, pH 7.4 for 5 minutes at 48C. The cells were then washed and stained with X -gal solution (1 mg /mL 5-bromo -4 -chloro -3 -indolyl -b -galactopyranoside, 5 mM K 4 Fe(CN ) 6 , 5 mM K 3 Fe( CN ) 6 , 2 mM MgCl 2 in PBS, pH 6.5 ) for 12 -18 hours at 378C. Blue staining of cell nuclei identified transduced cells. Mockinfected cells and cells transduced with other adenoviral vectors served as controls.
Dose -response curves
HT-29 and SW 620 cells were seeded in six -well plates at 1Â10 5 total cells and incubated for 24 hours at 378C. One six -well plate was infected with 200 l media (mock ); the remainder were infected with Ad -LacZ, Ad -E2F -1, Adp21 WT , or Ad -p21 -PCNA at increasing MOI (10, 25, 50, 100, and 150 ) for a period of 2 hours. Medium supplemented with 5% FBS and 1% penicillin / streptomycin was added and allowed to incubate for 5 days. After trypsinization, a cell count was obtained using a Coulter Counter ZM and trypan blue exclusion assays were performed. Approximate IC 25 ( concentration that inhibits 25% of viable cell growth compared to controls ) values were calculated based on total viable cells and IC 25 values were used for the remainder of the experiments.
Virus infection
Cells were seeded at 2.5Â10 4 cells /mL in 75-mm flasks and allowed to incubate for 24 hours, at which time the cells Cancer Gene Therapy Cell viability, cell count, and cell cycle analysis
Following viral infections, cells were harvested at 1 -, 3-, and 5 -day time points. For cell cycle analysis, 1Â10 6 cells were washed twice with ice -cold PBS, fixed in 70% cold ethanol, and stored at 48C until all time points were collected. Samples were then prepared for flow cytometric analysis as described previously. 4, 5 Flow cytometric analysis was performed using a FACscan ( Becton Dickinson, Mountain View, CA ). Data was analyzed using a CellFit cell -cycle analysis program (version 2.01.2 ).
Western blot analysis
For the detection of E2F -1 and p21 proteins, cells were lysed in lysis buffer as described previously. 4, 5 The protein concentrations were determined by the Bio -Rad protein assay ( Bio -Rad, Hercules, CA ). Thirty micrograms of total protein was loaded per lane and resolved in an 8% or 15% sodium dodecyl sulfate (SDS )-polyacrylamide gel. Proteins were transferred overnight to a polyvinylidene difluoride membrane (Amersham, Arlington Heights, IL ) and immunoblotted using p21, E2F -1 mAbs and actin polyclonal antisera (Sigma, St. Louis, MO ). Anti -mouse and antirabbit secondary antibodies conjugated to horseradish peroxidase were used and ECL reagents were used to detect the signals according to the manufacturer's instructions ( Amersham ).
Confirmation of apoptosis
Morphology associated with apoptotic cells was inspected by centrifuging 15,000 cells onto a microscope slide and staining with Wright / Giemsa stain. DNA fragmentation was confirmed by flow cytometry and apoptosis estimated by quantitation of the sub -G1 population. Poly( ADP-ribose ) polymerase (PARP ) cleavage assay has been show to be a sensitive method for detection of apoptosis. 40 -42 PARP cleavage assays were performed using a monoclonal mouse anti -PARP antibody ( Calbiochem, Oncogene Research Products, La Jolla, CA ) at a dilution of 1:100.
Protein stability assay
HT-29 and SW620 cells were seeded at 2.5Â10 4 cells/mL in 75 -mm flasks ( three flasks per combination therapy) and allowed to incubate for 24 hours, at which time the cells were 35% confluent. Cells were treated with adenoviral vectors at IC 25 concentrations for 2 hours and then fresh media was added. Five days following viral infection, cycloheximide was then added at a concentration of 100 g/ mL to each flask and then harvested at 0, 8, and 18 hours following drug treatment. Detection of E2F -1 protein by Western blot was carried out as described above.
Semiquantitative RT -PCR
Total RNA was extracted from cells 5 days following infection with the SV total RNA isolation system (Promega, Madison, WI ). One microgram of total RNA was used in a two-enzyme reaction that synthesizes and amplifies cDNA from a specific target mRNA in one tube (Access RT-PCR system, Promega, Madison, WI ). AMV reverse transcriptase is used for first -strand cDNA synthesis and Tf1 DNA Polymerase for second -strand cDNA synthesis in the presence of 50 pmol of transcript-specific primers for E2F -1 (forward primer: 5 0 -CTCGCAGCTCATCTC -3 0 and reverse primer: 5 0 -ATGAGCTGGATGCCCTCAAG -3 0 ). The RT-PCR conditions were established such that amplification of the cDNAs was dependent on the concentration of the corresponding RNA. RT-PCR of the housekeeping gene, -actin, was also amplified to verify equal loading of RNA.
Transactivation of CMV promoter assay
To determine if adenoviral vectors had an effect on CMV promoter activity, we performed a dose -response assay in which SW620 cells were coinfected with a constant amount of Ad -LacZ ( MOI 50 ), which was determined to result in -galactosidase activity in the linear range, along with increasing MOI of Ad -E2F -1, Ad -p21 WT , or Adp21 -PCNA . Cells were allowed to incubate for 72 hours following treatment with adenoviruses to allow forgalactosidase expression. The presence of -galactosidase activity was determined by monitoring the hydrolysis of o -nitrophenyl -1--D -galactopyranoside ( ONPG ) quantitatively using a -Gal assay kit ( Invitrogen, Carlsbad, CA ), as instructed by manufacturers. Briefly, cells were harvested 72 hours post infection with adenoviral combinations and then lyzed by resuspending in lysis buffer and subjecting to three freeze /thaw cycles in liquid nitrogen. Ten microliters cell lysate was then added to ONPG and 1Â cleavage buffer and incubated at 378C for 30 minutes. Following addition of 500 l stop buffer, -galactosidase activity in the supernatant was measured as absorbance at 420 nm. Protein concentration was then determined and specific activity of the lysate calculated.
In vivo combined treatment of transplanted human colon cancer cells
Tumors were formed by injecting 1Â10 7 HT-29 and SW620 cells into athymic Balb/c nu /nu male mice ( 6-8 weeks, Charles River Laboratories, Wilmington, MA ). Anesthesia was induced by intraperitoneal ( i.p. ) injection of ketamine ( 37.5 mg / kg) and xylazine (5 mg /kg ). The cells were injected subcutaneously into the bilateral flanks of the mice. Ten days later, palpable tumors were randomized to be directly injected with Ad -E2F -1 ( 1Â10 9 pfu ), Ad -LacZ (1Â10 9 pfu ) alone, or a combination of Ad -E2F -1 (5Â10 8 pfu), Ad -LacZ ( 5Â10 8 pfu ), or Ad -p21 -PCNA (5Â10 8 pfu ), for a total MOI of 100. PBS was injected as a mock control. Subcutaneous injections were performed twice per week, with a total of six treatments. Each injection of purified virus was diluted in total volume of 100 l PBS and administered
Cancer Gene Therapy p21/E2F-1 gene therapy in colon cancer MJ Elliott et al in a single pass of a 27.5-gauge hypodermic needle using gentle, constant infusion pressure. Tumors were measured immediately before each treatment, and tumor size was estimated using the following formula: length (mm )Âwidth ( mm )/2. Animal survival was closely monitored and no signs of systemic toxicity were observed in animals receiving the recombinant adenoviruses. Animal experiments were performed in accordance with institutional guidelines and approved by the University Committee on the Use and Care of Animals.
Statistical analysis
Statistic analysis was performed by Student's t test. P <.05 was considered statistically significant.
Results
Transduction efficiency of adenoviral vectors
To estimate the transduction efficiency of adenoviral vectors, the two human colon cell lines were infected with AdLacZ at MOI ranging from 25 to 150. At MOI of 20 -75 or greater, over 85% of cells demonstrated nuclear staining for -galactosidase in both cell lines. A dose -dependent increase in the intensity of -galactosidase staining was demonstrated with increased MOI up to 100 (data not shown). No significant cytotoxicity was observed with MOI up to 150.
Dose response assays
Dose-response curves were generated for each of the viral vectors in both of the colon cancer cell lines using trypan blue exclusion assay to estimate total viable cells ( data not shown). IC 25 -PCNA protein 5 days after infection in both the HT-29 and SW 620 cell lines (Fig 1 ) . The E2F -1/ p21
WT combination therapy showed a significant decrease in E2F -1 protein expression compared to E2F -1 alone in the SW620 cell line but demonstrated similar levels in the HT-29 cells. Conversely, the E2F -1/p21 -PCNA combination resulted in markedly increased E2F -1 expression compared to Ad -E2F -1 treatment alone in both cell lines. These results demonstrate a regulatory mechanism between p21 and E2F -1 in which the PCNA -binding domain of p21 has a significant effect on the expression level of E2F -1. Additionally, both cell lines showed a decrease in p21 -PCNA protein levels in the E2F -1 /p21 -PCNA combination therapy compared to p21 -PCNA gene therapy alone. Actin was used as an internal loading control. -PCNA alone exhibited 25% and 16% cell death, respectively. The E2F -1 /p21 -PCNA combination effect on cell death is greater than the single-therapy additive values ( P <.05 for both cell lines), thus suggesting a cooperative effect on cell death. The combination of E2F -1/ p21 -PCNA resulted in significantly greater cell death compared to E2F -1 /p21
Effect of adenoviral vector -mediated expression on cell viability and proliferation
WT treatment (P < .05 for both cell lines ). Inhibition of cell proliferation was greatest following E2F -1 /p21 -PCNA combination therapy in both cell lines, as shown in Figure 2B , suggests a cooperative effect as well. In agreement with other studies, 38 the overexpression of the p21 -PCNA inhibited cell growth to a greater extent than overexpression of p21 WT in both cell lines ( P <.05). Although growth inhibition was seen following infection with all of the adenoviruses ( excluding Ad -Lac -Z ), maximal inhibition of cell proliferation was only achieved with the E2F -1 /p21 -PCNA combination. The E2F -1/ p21 -PCNA combination treatment resulted in significantly decreased cell proliferation compared to either treatment alone in both cell lines ( P <.05 ). The combination of E2F -1/ p21 -PCNA resulted in significant inhibition of cell growth compared to E2F -1/ p21
WT treatment in HT-29 cells (P < .05), but not in SW620 cells. Notably, the cell growth in the SW620 cells infected with Ad -E2F -1 /Ad -p21
WT combination therapy exceeded that found in either of the separate therapies with Ad -E2F -1 or Ad -p21
WT by 5 days post treatment, supporting the previously observed negative regulation between p21
WT and E2F -1. 
combination therapy, which may be due to alterations in the p21 /pRb /E2F -1 pathway in this cell line.
Effects of adenoviral vector -mediated expression on cell cycle
To further investigate the mechanisms of E2F -1, p21, and mutant p21 interactions, cell cycle distribution following the Ad -E2F -1, Ad -p21 WT , and Ad -p21 -PCNA infections alone or in combination was analyzed. Figure 3A shows control ( mock and LacZ ) cell cycle distribution in both cell lines at 3 days following treatment. Cells overexpressing p21
WT or p21 -PCNA exhibited an increase in the G1 population in both cell lines by 3 days post infection. However, the E2F -1 -overexpressing cells demonstrated an increase in G2 /M phase population with a concomitant decrease in G1 phase. In cells overexpressing both E2F -1 and p21 WT , the p21-mediated G1 arrest was counteracted in both cell lines. However, E2F -1 could not inhibit the G1 arrest induced by p21 -PCNA even though the protein expression level of E2F -1 was highest in these cells. Figure 3B illustrates the percentage of cells found in G1 phase 3 days following treatments. These data suggest that the ability of p21 to interact with PCNA is essential for E2F -1 counteraction of p21-induced G1 arrest. WT or p21 -PCNA . Figure 4B graphically demonstrates the percentage of cells found in the subG1 population 5 days following gene transfer. The greatest subdiploid population was exhibited in the cells infected with the Ad -E2F -1 /Adp21 -PCNA combination therapy and was greater than the combined total of individual treatments with each virus. These findings suggest a cooperative effect between E2F -1 and p21
-PCNA on apoptotic cell death. In both cell lines, E2F -1 /p21 -PCNA combination treatment resulted in significantly greater DNA fragmentation compared to either treatment alone in both cell lines ( P <.05 ). The combination of E2F -1/ p21 -PCNA resulted in significantly greater DNA fragmentation compared to E2F -1 /p21
WT treatment ( P <.05 ).
Cell death is due to apoptosis
We have demonstrated previously in a number of different cell lines that E2F -1 -induced DNA fragmentation is due to apoptosis by using in situ TUNEL staining and Wright / Giemsa stain. 4, 5 To determine if the enhanced death and DNA fragmentation seen in the Ad -E2F -1 /p21 -PCNA combination therapy was due to apoptosis, Wright / Giemsa -stained cells were examined for morphological changes consistent with apoptosis including cytoplasmic blebbing, chromatin condensation, nuclear fragmentation, and the appearance of apoptotic bodies. To estimate the percentage of apoptotic cells in each sample, 1000 cells were counted and scored as either normal or apoptotic ( condensed, intense chromatin staining, and nuclear fragmentation ). Five days following infection with Ad -E2F -1, alone or in combination with p21 adenoviruses, evidence of apoptosis was observed ( data not shown). The degree of the formation of apoptotic cells in each sample correlated with the extent of DNA fragmentation estimated in the flow cytometric analysis.
In addition to internucleosomal DNA fragmentation and the cellular morphological markers seen during apoptosis, a cascade of molecular events can serve as early biochemical markers, including activation of the caspasefamily of proteins resulting in PARP cleavage. 40 -42 Cleavage of the nuclear enzyme PARP by caspase-3 (Cpp32/ YAMA / apopain ) has been proposed as one of the earliest events in the execution phase of apoptosis. 43 -46 Western blot analysis confirmed cleavage of PARP by 5 days post treatment in SW620 cells treated with Ad -E2F -1 alone or in combination with both p21 adenoviruses (Fig 5B ) . Therefore, these data confirm apoptosis as the mechanism of cell death and the activation of the caspase cascade in SW620 cells.
The 89 -kDa PARP apoptotic fragment was not detected in the HT-29 cell line. However, down -regulation of the full -length ( 113 -kDa ) PARP protein was evident in all of the cells infected with Ad -E2F -1 alone or in combination with p21 adenoviruses. Although we could not detect the apoptotic PARP fragment in the HT-29 cells, we believe apoptosis is the mechanism of death due to the Enhanced expression of E2F -1 protein in the E2F -1 / p21 -PCNA combination gene therapy is not due to altered protein stability Studies show that p21 can affect protein stability of some ubiquinated proteins due to increased proteasome degradation 24 and E2F -1 degradation is mediated by the ubiquitinproteasome pathway. 47 Therefore, we suspected that protein stability might be a factor related to the altered expression of E2F -1 in the combination therapies. E2F -1 protein half -life was measured by determining the level of protein at various time points following treatment with the protein synthesis inhibitor, cycloheximide. As shown in Figure 6 , E2F -1 protein was similar at each time point following cycloheximide treatment ( 0, 8, 18 hours ) in each sample and therefore protein stability does not appear to be a factor related to the increase or decrease of E2F -1 protein expression detected in the combination treatments.
RT -PCR analysis of E2F -1 mRNA expression
To investigate whether the enhanced protein expression of E2F -1 in the E2F -1 /p21 -PCNA combination therapy was associated with an increase in E2F -1 mRNA, we compared the abundance of E2F -1 mRNA by RT-PCR analysis following single and combination therapies with E2F -1. We reproducibly found increased expression of E2F -1 mRNA in the E2F -1 /p21 -PCNA -treated cells compared to the E2F -1 -or E2F -1/ p21
WT -expressing cells (Fig 7 ) . Figure 6 The effect of combination therapy on protein stability. SW620 cells were treated by Ad -E2F -1 alone or in combination with Ad -p21 wt or Ad -p21 -PCNA . Five days following viral infections, cycloheximide at 100 g / mL was added to each flask and harvested 0, 8, and 18 hours later. E2F -1 protein levels were assessed by immunoblotting with anti -E2F -1 as described. Blot is representative of two experiments. Actin was used as a control to demonstrate equal loading and transfer of protein. 
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Although not strictly quantitative, these results imply that increased E2F -1 expression may be due to increased E2F -1 mRNA levels.
p21
-PCNA enhances transactivation of CMV promoter
To investigate the ability of our adenoviral vectors to effect activity of the CMV promoter, coinfection with a constant amount of Ad -LacZ (MOI 50 ) and increasing amounts of Ad -E2F -1, Ad -p21 WT , or Ad -p21 -PCNA was performed and -gal activity measured. Marked stimulation of the CMV promoter was observed (Fig 8) with increasing MOI of Ad -p21 -PCNA . This increase occurred with or without coinfection of Ad -E2F -1. Coinfection with Ad -p21
WT had little effect on -gal activity with or without E2F -1 expression. These results suggest that overexpression of p21 -PCNA ( but not p21 WT ) activates CMV promoter transcription in these viral vectors.
In vivo treatment of human colon cancer cell xenografts
To determine whether our in vitro studies translated into a similar response in vivo, we evaluated the antitumor effects of combination gene therapy with E2F -1 and p21 -PCNA adenoviral vectors. Single virus injections were performed at MOI 100 and combination virus injections were at MOI 50 each for a total of MOI 100. As shown in Figure 9 , E2F -1 adenovirus alone inhibited tumor growth approximately 50% by day 16 in both HT-29 and SW620 cells. P21 -PCNA adenovirus alone had no effect on tumor growth. When combined, E2F -1 and p21 -PCNA adenovirus -mediated gene therapy caused approximately 95% decrease in tumor volume compared with LacZ control in the SW620 metastatic cell line, which was statistically significant ( P <.05). The combined gene therapy of E2F -1 and p21 -PCNA had no effect on tumor volume reduction in HT-29 xenografts compared to LacZ -treated tumors and, quite surprisingly, the presence of p21 -PCNA completely inhibited any of the tumor suppressor effects seen with E2F -1 alone in vivo. In SW620 cells, the combination of E2F -1/ p21 -PCNA treatment significantly reduced tumor volume compared to E2F -1 treatment at MOI 100, as well as all other treatments ( P <.05). Because the E2F -1 /p21
-PCNA combination treatment was not at all effective in inhibiting tumor growth in HT-29 cells, further experiments using the E2F -1 MOI 100 control were not performed for this cell line.
Discussion
This study was designed to investigate the effectiveness of a combination therapy in vitro and in vivo using genes encoding the transcription factor, E2F -1, and a C -terminal deletion mutant of p21 ( p21 -PCNA ) lacking the PCNAbinding domain. We used an adenoviral vector system to transfer the genes to two colon cancer cell lines, HT-29 ( primary ) and SW620 ( metastatic ), and analyzed the effect of this combination gene therapy on cell cycle regulation and apoptosis. We have shown previously that overexpression of E2F -1 efficiently triggers apoptotic cell death in a number of cell lines and involves caspase-3 activation and PARP cleavage. 4, 5 Here, for the first time, we show that coexpression of E2F -1 and p21
-PCNA results in a cooperative effect on cellular apoptosis in vitro. However, this gene combination was only effective in tumor growth inhibition of SW620 (metastatic ) colon cancer cell line in vivo. The results of this study also suggest a significant role for p21:PCNA interaction domain in the modulation of E2F -1-mediated regulation of cell cycle transition.
A growing body of evidence points to an opposing relationship between E2F -1 and p21 in both cell cycle control and mediation of apoptosis. 16 -29 Transciptional targets of E2F -1 include cdk2 and pcna genes favoring cell cycle progression. 7 -9 CDK2 is the catalytic partner of two cyclins involved in S phase progression, cyclin A and E, whereas PCNA plays an essential role in DNA replication as an auxiliary protein of Pol, the enzyme responsible for the replication of chromosomal DNA. In vitro studies have shown that p21 inhibits processive DNA synthesis through a PCNA -dependent mechanism 48 and the formation of ( n = 10 ) ( 6 ) E2F -1 MOI 100 ( n = 9 ).
Cancer Gene Therapy p21/E2F-1 gene therapy in colon cancer MJ Elliott et al cyclin-CDK complexes. 19 -24 Recently, much attention has been focused on the CDK2 -and PCNA -binding domains of p21 and their importance in facilitating G1 and G2 cell cycle arrest. Experiments utilizing N -or C -terminal deletion mutants of p21, or p21 mutants containing point mutations in the CDK2-or PCNA -binding domains provide consistent data that show if p21 has lost the ability to translocate to the nucleus, it can no longer inhibit cell cycle progression. 36, 37, 51 This observation is true even with the retention of p21's ability to inhibit CDK2 activity, 36 ,51 which appears to be a requirement for inhibition of cell cycle progression in addition to nuclear localization. In the present study, we used an adenoviral vector expressing a C -terminal deletion mutant p21 gene ( Ad -p21 -PCNA ). Characterization of the p21 -PCNA protein reveals that it does not bind PCNA but still maintains the ability to inhibit CDK2 activity and translocate to the nucleus. 38 Figure 3 , A and B demonstrate that overexpression of p21 -PCNA induced a G1 arrest that was equivalent or greater than the p21 WT -induced G1 arrest. Thus, in agreement with previous studies by Prabhu et al, 38 the binding and inactivation of PCNA by p21 is not required for the induction of a G1 arrest. Furthermore, as shown in Figure 3 , A and B, when E2F -1 was coexpressed with p21 WT , the cells accumulated in G2 / M, but when coexpressed with p21 -PCNA , the cells still accumulated in G1 phase. Therefore, our results also imply that the PCNA interaction domain of p21 is vital for the ability of E2F -1 to counteract a p21 -induced G1 arrest.
In addition to, but apparently independent of its transcriptional function, E2F -1 possesses an apoptotic function. 33 According to several studies, p21 has been shown to oppose apoptosis following a variety of apoptotic stimuli. 40,50 -52 However, little data exist regarding the effect of p21 on E2F -1 -mediated apoptosis. Even less is known about the function of the CDK2 -and PCNA -binding domains of p21 in the inhibition of an apoptotic signal, although the latter appears to be more important. Evidence from several studies indicate that there are cytoplasmic factors that p21 can deactivate to inhibit apoptosis including ASK1 (apoptosis signal -regulating kinase 1) and caspase-3. 47, 49 Interestingly, recent data indicate that treatment with the chemotherapeutic drug, camptothecin, results in caspase -mediated cleavage of p21 resulting in the production of a 15-kDa N -terminal fragment of p21 that does not bind to PCNA. 37 The cleavage of p21 results in the conversion of cancer cells from growth arrest to apoptosis and is thought to be a critical step in the acceleration of chemotherapyinduced tumor cell death. 37 This evidence suggests that the ability of p21 to bind to PCNA may be a requirement for p21 -mediated inhibition of apoptosis. Our results support these studies. As demonstrated in Figure 4 , wild -type p21 inhibited apoptosis induced by E2F -1 in the SW620 cell line, although it did not affect the level of E2F -1 -mediated apoptosis in the HT-29 cells. However, p21
-PCNA did not inhibit E2F -1 -induced apoptosis but in fact, enhanced the apoptotic effect in both cell lines. These data suggest that the ability of p21 to bind and inactivate PCNA may play an important role in the inhibition of E2F -1 -mediated apoptosis, and that removal of the PCNA -binding domain of p21 augments E2F -1 -induced apoptosis. In addition, because apoptosis occurred even though the E2F -1 /p21 -PCNA -overexpressing cells arrested in G1, the mere inhibition of cell growth is not sufficient to inhibit apoptosis.
It is not clear why the p21 C -terminal deletion mutant enhanced E2F -1 -mediated apoptosis. One explanation may be the increased levels of E2F -1 protein detected in the cells coinfected with Ad -E2F -1 and Ad -p21 -PCNA . Because the adenoviruses used in this study contain a constitutive CMV promoter, we expected the expression levels of E2F -1 to be relatively similar in all therapy combinations. However, we consistently found significantly higher levels of E2F -1 protein in the cells overexpressing both E2F -1 and p21 -PCNA . Further, in SW620 cells infected with Ad -E2F -1 and Ad -p21 WT , an actual decrease in E2F -1 expression was detected. Because p21 has been shown to effect proteasome degradation, 24 we suspected that protein stability might be a factor contributing to the altered levels of E2F -1. However, our protein stability experiments suggest otherwise. As demonstrated in Figure 6 , protein stability of E2F -1 was similar at each time point in all combination treatments up to 18 hours following cycloheximide treatment.
Next we performed RT-PCR experiments to determine if the increased E2F -1 protein expression was associated with increased levels of E2F -1 mRNA. RT-PCR analysis demonstrated that E2F -1 mRNA levels are greatest in cells overexpressing both E2F -1 and p21 -PCNA (Fig 9 ) , and lowest in the E2F -1/ p21
WT -treated cells. Although only semiquantitative at best, this finding was reproducible and the RT-PCR results correspond well with protein expression levels (Fig 1 ) . Furthermore, -galactosidase activity assays confirmed the ability of p21 -PCNA to up-regulate CMV promoter activity and accounts for the increase in E2F -1 mRNA and protein levels ( Fig 7 ) .
To determine if our in vitro studies translated into a similar response in vivo, we evaluated the antitumor effects of combination gene therapy with E2F -1 and p21 -PCNA adenoviral vectors. It has been well documented that adenovirus -mediated E2F -1 has an antitumor efficacy in a variety of tumors attributable to both the E2F -1 tumor suppressor gene and the adenovirus delivery vector. In the animal model of human colon cancer, E2F -1 adenovirus alone inhibited tumor growth approximately 50% in both HT-29 and SW620 cells. P21 -PCNA adenovirus alone had no effect on tumor growth. There was a significantly enhanced response when these modalities were combined to treat the SW620 metastatic cell line in vivo that was greater than the antitumoral effect of doubling the amount of Ad -E2F -1. However, Ad -p21 -PCNA did not enhance E2F -1-mediated tumor suppression in the HT-29 xenografts but in fact, totally inhibited any antitumor effect demonstrated with Ad -E2F -1 alone. These data offer the possibility of enhanced antitumor activity with combined gene therapy in colon cancer metastases.
In conclusion, the coinfection of Ad -E2F -1 and Adp21 -PCNA enhances E2F -1 -mediated apoptosis and cell growth inhibition in colorectal cancer cells in vitro. This effect of Ad -p21 -PCNA is associated with increased expression of E2F -1 when coinfection is performed, perhaps as a result of stimulation of the CMV promoter transcriptional activity by Ad -p21 -PCNA . In vivo studies demonstrate that this combination is only effective against the xenografts established from the metastatic colon cancer cell line, SW620. These findings provide a potentially promising approach for the treatment of advanced metastatic colorectal cancer. In addition to the therapeutic implication of these results, this study also provides further evidence of the importance of the p21:PCNA -binding domain in mediating the complex cell cycle interaction between E2F -1 and p21.
